title: Formulations of fentanyl for the management of pain.
abstract: Fentanyl is an opioid initially developed for parenteral administration. While oral administration is not an option due to a high first-pass metabolism, its high potency and lipophilicity have made a number of new routes of administration feasible. The transdermal therapeutic system offers an excellent option for long-term treatment of cancer and chronic pain, achieving stable plasma concentrations over the treatment period. The recent change from reservoir to matrix systems has made these systems more convenient to wear and safer to use, while being bioequivalent. In contrast, the patient-controlled iontophoretic transdermal system has been developed to enable on-demand delivery of transdermal bolus doses of fentanyl to treat postoperative pain. It offers a needle-free system to provide patient-controlled analgesia otherwise offered by intravenous pumps. However, due to technical difficulties the system is currently not clinically available. Oral transmucosal fentanyl utilizes the rapid uptake through the buccal mucosa to achieve high plasma concentrations rapidly and is indicated to treat breakthrough pain in patients who are not opioid-naive. The recently introduced fentanyl buccal tablets offer slightly better pharmacokinetics for the same indication. The intranasal route is another option to achieve rapid uptake of fentanyl, and is currently being investigated to provide acute and breakthrough pain relief. Transpulmonary administration of fentanyl remains experimental and this route of administration is not yet in clinical use. Overall, the specific pharmacological and physicochemical properties of fentanyl have made this compound highly suitable for novel routes of administration in a range of clinical indications.
authors.affiliation: Department of Anaesthesia and Pain Medicine, Royal Perth Hospital, Perth, Western Australia, Australia.
authors.forename: Sina
authors.initials: S
authors.lastname: Grape
authors.forename: Stephan A
authors.initials: SA
authors.lastname: Schug
authors.forename: Stefan
authors.initials: S
authors.lastname: Lauer
authors.forename: Barbara S
authors.initials: BS
authors.lastname: Schug
mesh_terms: D000278:Administration, Buccal; D000279:Administration, Cutaneous; D000284:Administration, Oral; D016058:Analgesia, Patient-Controlled / Q000639:trends*; D000701:Analgesics, Opioid / Q000493:pharmacokinetics; D002626:Chemistry, Pharmaceutical; D002908:Chronic Disease; D004304:Dosage Forms; D016503:Drug Delivery Systems; D005283:Fentanyl / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D007478:Iontophoresis / Q000379:methods; D009061:Mouth Mucosa; D009369:Neoplasms / Q000378:metabolism; D010146:Pain / Q000188:drug therapy* / Q000378:metabolism; D010147:Pain Measurement; D010149:Postoperative Pain / Q000188:drug therapy; D017060:Patient Satisfaction; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D013810:Therapeutic Equivalency
chemical_list: D000701:Analgesics, Opioid; D004304:Dosage Forms; D005283:Fentanyl